Impact of Apolipoprotein E4 on blood-brain barrier integrity in target replacement murine models: a systematic review and meta-analysis.

Overview

1. UK Dementia Research Institute at the University of Edinburgh, 49 Little France Crescent, Edinburgh, EH16 4SB UK
2. UK Dementia Research Institute Centre for Vascular Dementia Research, British Heart Foundation, University of Edinburgh, Edinburgh, UK
3. Institute for Neuroscience and Cardiovascular Research (INCR), University of Edinburgh, Chancellor’s Building, Edinburgh, UK

Abstract

Background: The E4 variant of Apolipoprotein E (APOE) is a primary genetic susceptibility risk factor for late-onset Alzheimer’s disease and has been implicated in cerebrovascular dysfunction. Preclinical mouse models are widely used to study APOE4, but cohesive understanding of APOE’s role is still inconsistent and lacking. The aim of this study was to systematically review and synthesise evidence from preclinical mouse studies assessing APOE4 related effects on blood-brain barrier (BBB) integrity, vascular morphology and cerebral blood flow (CBF).

Main: A systematic search of MEDLINE, Embase, Scopus, and Web of Science was conducted (March-April 2025). Eligible studies included transgenic APOE-targeted replacement or knock-in mice reporting vascular outcomes (cerebral blood flow, blood brain barrier permeability, vascular measures). Risk of bias was assessed using SYRCLE and reporting quality with CAMARADES. Random-effects meta-analyses were conducted (where sufficient data was available), otherwise findings were narratively synthesised. Eighteen studies met inclusion. Outcome measures varied widely, including diverse approaches to CBF measurement (e.g. arterial spin labelling, autoradiography, DSC-MRI), immunohistochemical measures (e.g. collagen-IV, laminin, CD31), and diverse approaches to measurement of BBB leakage (e.g. fibronectin, fibrinogen, gadolinium-based ktrans). Seven studies contributed to meta-analysis: APOE4 mice showed a consistent reduction in CBF associated with APOE4 genotype (SMD = -2.87, 95% CI: -5.14 to -0.604, df = 2.66), and a negative non-significant trend towards reduced vascular morphology expression. Narrative synthesis identified three key mechanistic pathways linking APOE4 to vascular dysfunction: (i) insulin resistance and PI3K/AKT-mTOR signalling, (ii) Cyclophilin A–NFκB–MMP9 activation, and (iii) occludin/ECM remodelling. Risk of bias assessment revealed frequent shortcomings in randomisation, blinding, and sample size justification.

Conclusions: Preclinical evidence demonstrates that APOE4 drives alterations in vascular functioning primarily through involvement with pathways related to vascular metabolism, ECM remodelling and BBB leakage. However, heterogeneity in the model (e.g. age, sex, techniques), restricts direct comparability across studies. As such, standardisation or clarification of methodological approaches are necessary for rigorous assessment in the future.

Supplementary Information: The online version contains supplementary material available at 10.1186/s13195-026-02018-3.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper says that its authors' code is available on request: it was not published with the paper, so there is nothing to verify.

The paper's code and data availability statement is in the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none (its code is available on request), so it has no map.

Data

Datasets cited

• figshare:32354095, at figshare; found in DataCite

Data availability

All data generated or analysed during this study are included in this article and its supplementary information files. The extracted dataset and analysis code that support the findings are available from the corresponding author on reasonable request. The full database search strategies have been deposited on searchRxiv (DOI: 10.1079/searchRxiv.2025.01124). The review protocol was registered with PROSPERO (CRD420251010665): (https://www.crd.york.ac.uk/PROSPERO/view/CRD420251010665).

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 1, 28 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 4 authors, 7 keywords, 8 MeSH terms, 1 funder, 66 references.

Cite

This paper

Laing, K. K., Fialova, N., Wardlaw, J., & Montagne, A. (2026). Impact of Apolipoprotein E4 on blood-brain barrier integrity in target replacement murine models: a systematic review and meta-analysis. Alzheimer's research & therapy, 18(1), 119. https://doi.org/10.1186/s13195-026-02018-3

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.1186/s12974-026-03888-y

Integrated imaging and molecular profiling reveals APOE4-associated neurovascular and glial disruptions in young adult mice.

Journal: Journal of neuroinflammation

In common: Alzheimer's / dementia, mouse, 6 references

[2] doi:10.64898/2026.03.01.708815

APOE4 Genotype is Associated with Reduced Cortical VEGFR2 ( <i>KDR</i> ) Transcript Levels Independent of Endothelial Abundance: An AMP-AD RNA-seq Pilot Study

Journal: bioRxiv (preprint)

In common: Alzheimer's / dementia, 6 references

[3] doi:10.1038/s43587-026-01204-0

Fibronectin mediates APOE4-driven blood-brain barrier dysfunction in Alzheimer's disease.

Journal: Nature aging

In common: Alzheimer's / dementia, mouse, 5 references

[4] doi:10.1186/s13024-026-00951-3

Cholesterol metabolism in neurodegenerative diseases: mechanisms and therapeutic advances.

Journal: Molecular neurodegeneration

In common: 4 references

[5] doi:10.3389/fnins.2026.1843319 [code]

Humanized APOE mouse brain volume increases over age irrespective of sex and APOE genotype: implications for translational validity to the human.

Journal: Frontiers in neuroscience

In common: Alzheimer's / dementia, clinical / translational, mouse, 3 references

[6] doi:10.1186/s13024-026-00965-x

Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice.

Journal: Molecular neurodegeneration

In common: Alzheimer's / dementia, mouse, 3 references

[7] doi:10.3389/fnagi.2026.1847611 [code]

APOE ε4-associated hippocampal atrophy trajectories across the Alzheimer's disease continuum: a systematic review, meta-analysis, and longitudinal validation.

Journal: Frontiers in aging neuroscience

In common: Alzheimer's / dementia, 4 references

[8] doi:10.1186/s12974-026-03970-5

Estrogen deprivation exacerbates Alzheimer's disease pathology through neuronal CTSS signaling.

Journal: Journal of neuroinflammation

In common: Alzheimer's / dementia, mouse, 2 references

[9] doi:10.1002/alz.71552

APOE*4 risk-modifying genes and drug targets in Alzheimer's disease through cell-type-specific genomic analyses.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

In common: Alzheimer's / dementia, 2 references

[10] doi:10.1111/acel.70494

Exceptional Longevity Modifying Allele APOE2 Promotes DNA Signaling Pathways Resisting Cellular Senescence in Human Neurons.

Journal: Aging cell

In common: Alzheimer's / dementia, 2 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.

Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.